Last reviewed · How we verify

Gonal-f®: follitropin alpha

Centre Hospitalier Chretien · FDA-approved active Small molecule Quality 5/100

Gonal-f®: follitropin alpha is a Small molecule drug developed by Centre Hospitalier Chretien. It is currently FDA-approved.

At a glance

Generic nameGonal-f®: follitropin alpha
SponsorCentre Hospitalier Chretien
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Gonal-f®: follitropin alpha

What is Gonal-f®: follitropin alpha?

Gonal-f®: follitropin alpha is a Small molecule drug developed by Centre Hospitalier Chretien.

Who makes Gonal-f®: follitropin alpha?

Gonal-f®: follitropin alpha is developed and marketed by Centre Hospitalier Chretien (see full Centre Hospitalier Chretien pipeline at /company/centre-hospitalier-chretien).

What development phase is Gonal-f®: follitropin alpha in?

Gonal-f®: follitropin alpha is FDA-approved (marketed).

Related